logo-loader
viewCircassia Group PLC

Circassia Pharma Plc - Total Voting Rights

RNS Number : 6511L
Circassia Pharmaceuticals Plc
01 May 2020
 

For immediate release

 

Circassia Group plc

 

Total Voting Rights Update

 

 

 

1 May 2020

 

In accordance with the requirements of the FCA's Disclosure and Transparency Rule 5.6.1, Circassia Group plc ("Circassia" or "the Company") (LSE: CIR) confirms that the Company's issued share capital consists of 375,692,819 ordinary shares of 0.08p each in issue, each with equal voting rights.  No shares are held in treasury.  

 

The above figure may be used by shareholders as the denominator for the calculations by which they will determine whether they are required to notify their interest, or a change to their interest, in the Company under the FCA's Disclosure Guidance and Transparency Rules.

 

-Ends-

 

For further information, please contact:

 

Circassia Group plc

Michael Roller, Company Secretary

 

+44 (0) 1865 405560

 

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
 
END
 
 
TVREANSFEDEEEEA

Quick facts: Circassia Group PLC

Price: 25.55

Market: LSE
Market Cap: £96.3 m
Follow

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: Circassia Pharmaceuticals' commercial development...

Circassia Pharmaceuticals PLC's (LON:CIR) CEO Steve Harris tells Proactive London's Andrew Scott they saw strong growth in the first half of the year alongside a reduction in costs and cash outflows. Revenues for the six months ended June 30 were up 40% year-on-year at £27.9mln, with the...

on 26/9/19